Anbin Chen

Anbin Chen

Auto-generated profile, based on publicly available information

Anbin Chen

Department of Neurosurgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 20092, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JWJiwei Wang
Jiwei Wang
ACAnbin Chen
Anbin Chen
ZXZhiwei Xue
Zhiwei Xue
JLJunzhi Liu
Junzhi Liu
YHYing He
Ying He
BHBin Huang
Bin Huang
There is an urgent need for novel diagnostic and therapeutic strategies for patients with Glioblastoma multiforme (GBM). Previous studies have shown that BCL2 like 13 (BCL2L13) is a member of the BCL2 family regulating cell growth and apoptosis in different types of tumors. However, the clinical significance, biological role, and potential mechanism in GBM remain unexplored. In this study, we showed that BCL2L13 expression is significantly upregulated in GBM cell lines and clinical GBM tissue samples. Mechanistically, BCL2L13 targeted DNM1L at the Ser616 site, leading to mitochondrial fission and high mitophagy flux. Functionally, these alterations significantly promoted the proliferation and invasion of GBM cells both in vitro and in vivo. Overall, our findings demonstrated that BCL2L13 plays a significant role in promoting mitophagy via DNM1L-mediated mitochondrial fission in GBM. Therefore, the regulation and biological function of BCL2L13 render it a candidate molecular target for treating GBM.

16 August 2023 in The FASEB Journal
Verified
Journal Article
Open access
CKCecilie Katrin Kristiansen
Cecilie Katrin Kristiansen
JFJessica Furriol
Jessica Furriol
ACAnbin Chen
Anbin Chen
Gareth SullivanGareth Sullivan
Gareth Sullivan
LBLaurence A. Bindoff
Laurence A. Bindoff
KLKristina Xiao Liang
Kristina Xiao Liang
Mutations in POLG , the gene encoding the catalytic subunit of the mitochondrial DNA (mtDNA) polymerase gamma (Pol‐γ), lead to diseases driven by defective mtDNA maintenance. Despite being the most prevalent cause of mitochondrial disease, treatments for POLG‐related disorders remain elusive. In this study, we used POLG patient‐induced pluripotent stem cell (iPSC)‐derived neural stem cells (iNSCs), one homozygous for the POLG mutation c.2243G>C and one compound heterozygous with c.2243G>C and c.1399G>A, and treated these iNSCs with ethidium bromide (EtBr) to study the rate of depletion and repopulation of mtDNA. In addition, we investigated the effect of deoxyribonucleoside (dNs) supplementation on mtDNA maintenance during EtBr treatment and post‐treatment repopulation in the same cells. EtBr‐induced mtDNA depletion occurred at a similar rate in both patient and control iNSCs, however, restoration of mtDNA levels was significantly delayed in iNSCs carrying the compound heterozygous POLG mutations. In contrast, iNSC with the homozygous POLG mutation recovered their mtDNA at a rate similar to controls. When we treated cells with dNs, we found that this reduced EtBr‐induced mtDNA depletion and significantly increased repopulation rates in both patient iNSCs. These observations are consistent with the hypothesis that mutations in POLG impair mtDNA repopulation also within intact neural lineage cells and suggest that those with compound heterozygous mutation have a more severe defect of mtDNA synthesis. Our findings further highlight the potential for dNs to improve mtDNA replication in the presence of POLG mutations, suggesting that this may offer a new therapeutic modality for mitochondrial diseases caused by disturbed mtDNA homeostasis.

17 September 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAnbin Chen
Anbin Chen
TYTsering Yangzom
Tsering Yangzom
YHYu Hong
Yu Hong
BLBjørn Christian Lundberg
Bjørn Christian Lundberg
GSGareth John Sullivan
Gareth John Sullivan
KLKristina Xiao Liang
Kristina Xiao Liang
In our research, we developed a 3D brain organoid model to study POLG-related encephalopathy, a mitochondrial disease stemming from POLG gene mutations. We utilized induced pluripotent stem cells (iPSCs) derived from patients with these mutations to generate cortical organoids, which exhibited typical POLG disease features, such as altered morphology, neuronal loss, and mtDNA depletion. We also identified significant dysregulation in pathways crucial for neuronal development and function, alongside upregulated NOTCH and JAK-STAT signaling pathways. Metformin treatment ameliorated many of these abnormalities, except for the persistent affliction of inhibitory DA GLU neurons. This novel model effectively mirrors both the molecular and pathological attributes of POLG disease, providing a valuable tool for mechanistic understanding and therapeutic screening for POLG-related disorders and other conditions characterized by compromised neuronal mtDNA maintenance and complex I deficiency. Highlights: We have successfully developed cortical organoid model that represents POLG-related disease. This model effectively replicates both histological and molecular signatures seen in the brains of patients. The cortical organoid model displays a range of features common in POLG-related disease, including neurodegeneration, mtDNA depletion, and neuronal complex I deficiency. The use of metformin supplementation in this model improved mitochondria protein and reduced cell death.

9 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAnbin Chen
Anbin Chen
SSSebastian Edgar Schmidke
Sebastian Edgar Schmidke
CKCecilie Katrin Kristiansen
Cecilie Katrin Kristiansen
KLKristina Xiao Liang
Kristina Xiao Liang
Background: Mutations in the POLG gene, encoding the catalytic subunit of mitochondrial DNA polymerase gamma, are the most common cause of mitochondrial diseases affecting the central nervous system. These mutations frequently result in neurodevelopmental disorders, yet the cellular and molecular mechanisms underlying POLG related encephalopathies remain poorly understood. In particular, how POLG mutations affect mitochondrial function, neural progenitor behavior, and early neurogenesis in the developing human brain has not been fully elucidated. Methods: To investigate the impact of POLG mutations on human neurodevelopment, we generated 3D cortical brain organoids from induced pluripotent stem cells (iPSCs) derived from a patient carrying compound heterozygous POLG mutations (A467T/W748S). Organoid development was monitored using immunohistochemistry, transmission electron microscopy, and live-cell mitochondrial assays. Single-cell RNA sequencing (scRNA-seq) was performed to profile cellular diversity and transcriptional changes. Organoids were treated with metformin, a known mitochondrial modulator, and mitochondrial function was assessed by measuring membrane potential (TMRE), ATP production, and mtDNA copy number. Western blotting and immunofluorescence were used to investigate AMPK–SIRT3–mTOR signaling and markers of mitochondrial dynamics and mitophagy. Statistical analyses were performed using unpaired t-tests or ANOVA, with p-values < 0.05 considered significant. Results: POLG mutant cortical organoids exhibited impaired neural differentiation, with expansion of stress-associated neural progenitors and reduced neuronal populations. scRNA seq analysis revealed transcriptional signatures of oxidative stress, mitochondrial dysfunction, and suppressed neurogenesis, particularly in a specific neural progenitor subpopulation. Metformin treatment significantly improved mitochondrial membrane potential, ATP output, and mtDNA copy number in POLG organoids. It also promoted neuronal differentiation and reduced reactive progenitor states. Mechanistically, metformin activated AMPK and SIRT3, inhibited mTOR, enhanced expression of mitochondrial fusion and biogenesis markers (OPA1, PGC-1α), and increased autophagic and mitophagic activity (LC3B, BNIP3). Conclusions: Our study demonstrates that POLG mutations disrupt early cortical development by impairing mitochondrial function and skewing progenitor fate. Metformin mitigates these effects by restoring mitochondrial homeostasis and promoting neurogenesis through the AMPK/SIRT3/mTOR axis. These findings offer mechanistic insights into POLG-related encephalopathy and support metformin as a candidate for therapeutic intervention in mitochondrial neurodevelopmental disorders.